The myelodysplastic syndromes (MDSs) comprise a group of disorders characterized by multistage progression from cytopenias to acute myeloid leukemia (AML). They display exaggerated apoptosis in early stages, but lose this behavior during evolution to AML. The molecular basis for loss of apoptosis is unknown. To investigate this critical event, we analyzed phosphatidylinositol (PI) 3 0 kinase signaling, implicated as a critical pathway of cell survival control in epithelial and hematological malignancies. PI 3 0 kinase activates Akt through its production of 3 0 phosphoinositides. In turn, the phosphoinositides are dephosphorylated by two lipid phosphatases, PTEN and SHIP-1, in myeloid cells. We studied primary MDS-enriched bone marrow cells and bone marrow sections by western blotting, immunohistochemistry, immunocytochemistry and quantitative PCR for components of the SHIP/PTEN/PI 3 0 kinase signaling circuit. We reported constitutively activated Akt, variable levels of PTEN and uniformly decreased SHIP-1 expression in MDS progenitor cells. Overexpression of SHIP-1, but not the phosphatase-deficient form, inhibited myeloid leukemic growth. Levels of microRNA (miR)-210 and miR-155 transcripts, which target SHIP-1, were increased in CD34 þ MDS cells compared with their normal counterparts. Direct binding of miR-210 to the 3 0 untranslated region of SHIP-1 was confirmed by luciferase reporter assay. Transfection of a myeloid cell line with miR-210 resulted in loss of SHIP-1 protein expression. These data suggest that miR-155 and miR-210/SHIP-1/Akt pathways could serve as clinical biomarkers for disease progression, and that miR-155 and miR-210 might serve as novel therapeutic targets in MDS.
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Introduction
The myelodysplastic syndromes (MDSs) are a heterogeneous group of hematological disorders with poorly understood pathophysiology (Corey et al., 2007) . The incidence of MDS is increasing because of more accurate diagnosis, improved classification of myeloid disorders, better supportive care and an aging population (Aul et al., 1998) . The World Health Organization has updated the classification schema by taking into account new understandings of how specific cytogenetic abnormalities like monosomy 7 and isolated 5q deletion in the clonal population affect the natural history of the disease (Vardiman et al., 2009) . Bone marrow from patients with early-stage MDS, such as refractory anemia (RA), RA with ringed sideroblasts or refractory cytopenia with unilateral dysplasia, is hypercellular and is characterized by increased intramedullary apoptosis of hematopoietic progenitors, resulting in inefficient hematopoiesis and peripheral cytopenias (Greenberg, 1998) . This ineffective hematopoiesis correlates with an elevation in proapoptotic cytokines such as TNF-related apoptosisinducing ligand (TRAIL), tumor necrosis factor a and FasL (Heaney and Golde, 1999) . As the disease progresses to late-stage MDS, apoptosis is reduced, a block in differentiation develops and blasts accumulate. Approximately 40-50% of those with high-risk disease (Greenberg et al., 2002) will progress to acute myeloid leukemia (AML). Progression of the disease over several years strongly supports a multistep evolution of the malignant MDS stem cell clone (Fenaux, 2004) . Activation of oncogenes or inactivation of tumor suppressor genes has not been well established in MDS, as they have in de novo AML. Complex cytogenetics and a poor therapeutic response to cytarabine are other features that distinguish MDS blasts from those in de novo AML (Corey et al., 2007) . Recognizing these differences, we set out to determine why apoptosis is dysregulated as MDS evolves to AML. Identification of molecular differences between low-and high-risk MDS will inform future clinical trials with targeted therapies, hopefully leading to improvement in outcome.
Phosphatidylinositol (PI) 3 0 kinase critically regulates cell survival and apoptosis mostly through Akt (Manning and Cantley, 2007) . The pleckstrin homology domain of Akt binding to PI-(3,4,5)P 3 results in the translocation of Akt to the plasma membrane, where it is phosphorylated within its catalytic loop at Thr308 and Ser473. Frequent elevation of Akt kinase phosphorylation in the bone marrow and peripheral blood mononuclear cells from high-risk MDS patients has been reported (Nyakern et al., 2006; Follo et al., 2007) , but its mechanism has not been elucidated. High-risk MDS patients also displayed high levels of activated Akt's downstream targets, such as phosphor-mTOR, but lowrisk MDS patients were more weakly positive and healthy donors were negative (Follo et al., 2007) . The lipid phosphatases PTEN and SHIP-1 are known to regulate the levels of phosphoinositides (Krystal, 2000) . Ubiquitously expressed, PTEN hydrolyzes the 3 0 phosphate of PI-(3,4,5)P 3 and is a well-established tumor suppressor in human cancers (Di Cristofano et al., 1998; Robertson et al., 1998; Cantley and Neel, 1999) . Expressed specifically in hematopoietic cells, SHIP-1 hydrolyzes the 5 0 phosphate of PI-(3,4,5)P 3 (Geier et al., 1997) . To date, there is no evidence of SHIP-1 acting as a tumor suppressor, although such a role in myeloid cells has been supported by abnormalities in SHIP-1-deficient mice (Helgason et al., 1998) . We therefore chose to investigate the PI 3 0 kinase-PTEN/SHIP-1-Akt pathway in MDS.
Results
As there are few cell lines or mouse models that resemble human MDS, we studied primary cells from patients to profile the activation states of the PI 3 0 kinase/Akt pathway. Akt is constitutively activated, as evidenced by phospho-Akt (Ser473), in whole-cell lysates of T and B lymphocyte-depleted bone marrow mononuclear cells from patients with late-stage MDS. Interestingly, Erk1/2 activity is near baseline when compared with normal CD34 þ cord blood cells ( Figure 1A ). We postulated that Figure 1B) . We next sought to analyze the regulators of Akt activation. Akt is activated by PI-(3,4,5)P 3 as produced by PI 3 0 kinase. The tumor suppressor PTEN serves as the 3 0 phosphoinositide phosphatase, and is frequently inactivated by epigenetic silencing (Dahia et al., 1999) . SHIP-1 is a 5 0 phosphoinositide phosphatase, expressed exclusively in hematopoietic cells Helgason et al., 1998; Krystal, 2000) . We found that PTEN levels were variably decreased in late-stage MDS. More striking is the fact that SHIP-1 was significantly decreased by western blot in one and absent in the remainder of the lysates from late-stage MDS-enriched myeloid cells ( Figure 1C ). SHIP-1 was expressed in high levels in U937 and HL60, two commonly studied AML cell lines (Supplementary Figure 1) . Immunocytochemical staining of bone marrow CD34 þ cells confirmed the loss of SHIP-1 in patients with late-stage MDS (RAEB and AML with myelodysplasia-related changes), while SHIP-1 in early-stage MDS (RARS and refractory cytopenia with multilineage dysplasia, RCMD) was positive ( Figure 1D ).
We therefore postulated that SHIP-1 acts as a tumor suppressor and is lost during progression of MDS. To confirm SHIP-1's role in myeloid colony growth, we transfected either wild-type or phosphatase-inactive SHIP-1(D673G) into 293T cells. The phosphatase activity of SHIP-1, as measured by phospho-Akt, was abrogated by the SHIP-1(D673G) mutant (Supplementary Figure 2) . We next determined the effect on apoptosis by transfecting wild-type and mutant SHIP-1 with green fluorescent protein (GFP) tags into THP-1 cells, which do not express endogenous SHIP-1. Transient transfection of wild-type SHIP-1 increased the proportion of apoptotic (Annexin V-positive) THP-1 cells compared with mutant SHIP-1 or vector alone, when gated for GFP (Figure 2a) . Further, expression of wild-type, but not phosphatase-defective SHIP-1, decreased the number of spontaneously growing colonies from primary AML cells ( Figure 2b ). We chose to use primary AML cells because culture and transfection of primary MDS cells have been technically difficult. Restoration of SHIP-1 activity in human leukemic cells and primary blasts increased apoptosis and decreased growth. These studies suggest that SHIP-1 can act as a tumor suppressor in human myeloid disease and is downregulated as MDS progresses from early-stage to late-stage disease.
We next addressed the molecular basis for the loss of SHIP-1. Genetic lesions in MDS are heterogeneous, but none have been reported in chromosome 2q37.1 where the SHIP-1 gene resides. Though found in Chinese patients with AML (Luo et al., 2004) , mutations in the coding region of SHIP-1 are rare in Caucasian patients (Gilby et al., 2007) . Having confirmed that SHIP-1 protein levels are decreased in these patients, we investigated three major mechanisms by which this effect is known to occur in other malignancies: increased destruction of SHIP-1 by proteasomes, hypermethylation and regulation of transcripts by microRNAs (miRs).
We first sought to determine if this could be explained at the transcript level by performing quantitative PCR for SHIP-1, PTEN and the adaptor molecule Gab2 on RNA harvested from MDS-enriched myeloid cells and normal CD34
þ cells. The levels of SHIP-1 and PTEN transcripts in MDS-enriched myeloid cells were about half of those found in normal CD34 þ stem cells (P values of 0.0002 and 0.0005, respectively, as shown in Figure 3a ). We also measured Gab2 mRNA levels, which were not significantly different from control CD34 þ cells. Epigenetic silencing of PTEN by hypermethylation was reported in several other malignancies (Zysman et al., 2002) . However, algorithm analysis of the human SHIP-1 promoter did not predict the presence of any CpG islands. To support this finding, incubation of SHIP-1-deficient cell lines with the hypomethylating agents, 5-azacytadine or decitabine, did not result in increased protein expression or transcript number of SHIP-1 (data now shown). While decreased levels of mRNA transcripts correlated with protein levels for PTEN, the decreased protein expression for SHIP-1 was more dramatic than what would be predicted by transcript levels, suggesting additional mechanisms.
Next, we considered protein degradation as SHIP-1 contains two PEST sequences, a signal peptide for ubiquitinylation (Ware et al., 1996) . SHIP-1's absence in K562 cells has previously been reported to be due to SHIP-1 expression in high-risk myelodysplastic syndromes DW Lee et al decreased protein half-life as well as reduced mRNA levels (Sattler et al., 1999) . When we treated U937 cells with the proteasome inhibitor lactacystin we did observe a modest increase in the expression of SHIP-1 (Figure 3b) . p21Waf1, whose level increases with proteasome inhibition, served here as a positive control. Ubiquitinylation of SHIP-1 was demonstrated in 293T cells transfected with SHIP-1 and HA-ubiquitin (Supplementary Figure 3 ). However, this does not entirely explain the significant decrease in protein expression for SHIP-1 observed in late-stage MDS patient-derived cells, and thus we considered translational suppression by miRNAs. Several lines of evidence link miRNAs to leukemias, suggesting possible roles for miRs in hematopoiesis and tumorigenesis. We hypothesized that the loss of SHIP-1 might also be due to translational repression by miRs. miR-155 has recently been shown to suppress SHIP-1 expression by binding to its 3 0 untranslated region (UTR) (Costinean et al., 2009; O'Connell et al., 2009; Pedersen et al., 2009; Yamanaka et al., 2009 (Figure 3c ).
To confirm that miR-210 contributes to SHIP-1 downregulation, we generated a luciferase reporter construct linked to the 3 0 UTR of SHIP-1 that was either unmodified or mutated at the pre-miR-210 complementary site. We cotransfected U937 cells with pre-miR-210 or control and either the mutant or unmodified luciferase-3 0 UTR-SHIP-1 construct. When compared with empty vector or control, expression of pre-miR-210 decreased luciferase reporter activity by 30%, suggesting that pre-miR-210 does interact with SHIP-1 (Figure 4a 
Discussion
MDSs constitute a set of diseases characterized first by excessive and later by the absence of apoptosis involving myeloid cells (Corey et al., 2007) . Aberrant PI 3 0 kinase/ Akt activity, which promotes cell survival, may contribute to disease progression from low-risk MDS to high-risk MDS, culminating in AML. We showed that PI 3 0 kinase/Akt was more active in high-risk MDS, which correlated with decreased levels of PTEN and SHIP-1. Our finding on human samples supports studies that showed myelodysplasia in PTEN þ /À SHIP À/À mice (Moody et al., 2004) . PTEN is a well-established tumor suppressor that regulates the PI 3 0 kinase/Akt pathway, and PTEN abnormalities have been reported to contribute to the development of prostatic, ovarian and breast cancer, and resistance to trastuzumab (Nagata et al., 2004) . In contrast, SHIP-1 is expressed exclusively in hematopoietic cells Helgason et al., 1998; Kalesnikoff et al., 2003) , and might be related to leukemia development.
By dephosphorylating phosphoinositides at the 5 0 position, SHIP-1 leads to the accumulation of PI- Immunohistochemistry staining for SHIP-1 was performed 48 h after the human myeloid leukemia cell line U937 was transfected with pre-miR-210. The histochemical staining was deconvoluted and quantified using NIH ImageJ software. Ten random measurements, scattered in the four quadrants of each picture, for each condition were analyzed and are presented as arbitrary units ( ± s.e.m.).
SHIP-1 expression in high-risk myelodysplastic syndromes DW Lee et al (3,4)P 2 , redirecting signaling away from effectors with pH domains that bind preferentially to PI-(3,4,5)P 3 , such as Akt. Although there has been no report of the role in human cancer (Gilby et al., 2007) , ablation of SHIP-1 gene in mice leads to myeloproliferative disease (Helgason et al., 1998; Lakhanpal et al., 2010) . SHIP-1 deficiency might explain other characteristics of MDS. Loss of SHIP-1 reduces the expression of CXCR4, the receptor for the stroma cell-derived factor-1, which modifies the interactions between the bone marrow niche and hematopoietic stem cells (Hazen et al., 2009) . Human CD34 þ cells from MDS patients do not respond to stroma cell-derived factor-1 effectively even though MDS patients have higher plasma stroma cell-derived factor-1 levels than healthy volunteers (Matsuda et al., 2004) . SHIP-1 also regulates apoptosis via its interaction with tyrosine-protein kinase Tec (Tomlinson et al., 2004) . Of note, Tec kinase is highly expressed in MDS samples (Sato et al., 1994) and contributes to myeloid cell survival (Melcher et al., 2008) . As SHIP-1 inhibits Tec activity, loss of SHIP-1 would augment Tecmediated cell survival in MDS.
Several possibilities could account for a decreased level of SHIP-1: epigenetic modification, decreased transcription, translational repression and increased protein breakdown. Our quantitative PCR detected approximately 50% decrease in SHIP-1 transcripts, which suggested epigenetic and/or transcriptional regulation. We also showed that SHIP-1 protein level was, at least in part, regulated by proteasomal degradation. As SHIP-1 contains a Src phosphorylation site, Src-dependent tyrosine phosphorylation of SHIP-1 promotes its ubiquitinylation, possibly through its association with the E3 ubiquitin ligase c-Cbl (Ruschmann et al., 2010) . In fact, our western blot analysis showed mild increase of SHIP-1 protein levels by a proteasome inhibitor. As we have also found that the Src family kinase Lyn is constitutively activated in MDS cells (data not shown), phosphorylation-dependent protein degradation may have contributed to the loss of SHIP-1. miRs are a newly discovered class of short, noncoding RNA species, which may serve as master switches in gene networks. Together with transcription and protein degradation, they affect protein levels (Whichard et al., 2011) . Both miR-155 and miR-210 were shown to bind to the 3 0 UTR of SHIP-1 mRNA; therefore, we expected they would inhibit the translation. Levels of both miRs were elevated several fold in CD34 þ cells from patients with high-risk MDS. Increased levels of miR-155 were also found among high-risk, not low-risk, MDS patients (Pons et al., 2009) . Downregulation of SHIP-1 expression by miR-155 activates the PI 3 0 kinase/Akt pathway (Costinean et al., 2009; Pedersen et al., 2009) . Expression of miR-155 enhances lipopolysaccharide-induced immune response and tumor necrosis factor-a (O'Connell et al., 2009; Pedersen et al., 2009) , and excess inflammatory cytokines, especially tumor necrosis factor-a, have been reported in MDS patients (Rosenfeld and List, 2000) . Aberrant expression of miR-155 has recently been found in natural killer leukemia/lymphoma cells that display increased level of phospho-Akt (Yamanaka et al., 2009) . In addition, miR-155 may stimulate the proliferation of MDS cells by inducing granulocyte colony-stimulating factor expression. Silencing of miR-155 in lipopolysaccharide-treated mice results in de-repression of C/EBPb and downregulates granulocyte colony-stimulating factor expression (Worm et al., 2009) . Upregulation of miR-210 regulates the hypoxic response of tumor cells and tumor growth (Huang et al., 2009 ). In a cellautonomous effect, MDS cells were found to grow more robustly under hypoxia conditions (Thompson et al., 2007) . The low oxygen tension found in the bone marrow microenvironment may provide a selection pressure on MDS cells to survive, stimulating miR-210 expression. In a positive feed-forward loop, miR-210 promotes survival by suppressing SHIP-1.
In this study, we showed that SHIP-1 was consistently decreased in high-risk MDS, not in low-risk MDS, suggesting a disease-specific tumor suppressor activity. Accumulation of genetic defects leads to loss of difference and apoptosis in MDS stem cells, but specific genetic or epigenetic lesions have not been identified. Our data suggest that high-risk MDS is associated with higher levels of two miRs that target SHIP-1. Thus, the miR/ SHIP/Akt pathway could serve as a clinical biomarker for disease progression, and miR-155 and miR-210 might serve as novel therapeutic targets in MDS.
Materials and methods
Cell culture, antibodies and reagents Human leukemia cell lines HL-60, THP-1 and U937 were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum and 2 mM L-glutamine and penicillin/streptomycin (GIBCO, Grand Island, NY, USA) and incubated in humidified incubators at 37 1C, 5% CO 2 . Commercially available antibodies used were Akt, phospho-Akt Ser473, phospho-Akt Thr308, phospho-Erk1/2 from Cell Signaling (Beverly, MA, USA); anti-phosphotyrosine (4G10), anti-actin and anti-SHIP-1 (rabbit polyclonal N-1 and murine monoclonal P1C1) from Santa Cruz Biotechnology (Santa Cruz, CA, USA); and p21Waf1 from BD Biosciences (San Jose, CA, USA). Site-directed PCR Mutagenesis Kit was purchased from Stratagene (La Jolla, CA, USA). Lipofectamine 2000, Neomycin (G418) and Zeomycin were purchased from Invitrogen (Carlsbad, CA, USA). Hygromycin was purchased from Sigma-Aldrich (St Louis, MO, USA). Lactacystin was purchased from BioMol (Plymouth Meeting, PA, USA).
Preparation of MDS-enriched and CD34
þ myeloid cells Bone marrow samples were previously obtained from MDS patients with RA with excess blasts (blasts are at least 5% but do not exceed 20% of bone marrow cells) or RA with excess blasts in transformation (blasts are >20% but less than 30%) according to the French-American-British classification system. RAEB-T is now known as AML with myelodysplasiarelated changes according to the World Health Organization (WHO) classification of tumors of hematopoietic and lymphoid tissues (Vardiman et al., 2009) . Samples were obtained after signed, informed consent, following institutional guidelines at the University of Texas -MD Anderson Cancer Center. Upon receipt of the specimen, mononuclear cells were SHIP-1 expression in high-risk myelodysplastic syndromes DW Lee et al first obtained by Ficoll-Hypaque centrifugation, followed by immunomagnetic depletion of CD3 þ and CD19 þ (Miltenyi Biotech, Auburn, CA, USA) cells. Normal CD34 þ cells were positively selected from umbilical cord blood. Human neutrophils were obtained from healthy adult volunteers, following informed consent. The neutrophil fraction was obtained by 6% dextran sedimentation, followed by Ficoll-Hypaque separation. Contaminating red blood cells were lysed with hypotonic saline, and the neutrophil pellet was washed with phosphate-buffered saline (PBS) before use. All cryopreserved samples were stored under vapor phase of liquid nitrogen until use. For CD34 þ isolation, fresh MDS bone marrows were processed in the MD Anderson Hematopathology Department. After washing and centrifugation, bone marrow mononuclear cells were further purified by magnetic beads (Miltenyi Biotec, Auburn, CA, USA) to obtain the CD34 þ fraction according to the manufacturer's instructions.
Immunoblotting of cell lysates
Patient samples were individually thawed and washed twice with sterile PBS. Patient samples and cell lines were lysed in 1% NP-40 lysis buffer with protease inhibitor cocktail (SigmaAldrich), 1 mM sodium orthovanadate (Sigma-Aldrich) and 1 mM phenylmethylsulfonyl fluoride (Sigma-Aldrich). p21Waf1 (BD Biosciences) immunoprecipitation was performed using protein A sepharose (Santa Cruz Biotechnology). Immunoblotting was performed by SDS-polyacrylamide gel electrophoresis, followed by transfer to a polyvinylidene fluoride (Millipore) membrane. After the membrane was incubated with the primary and secondary (goat anti-rabbit antiimmunoglobulin antibody conjugated to horseradish peroxidase, Bio-Rad) antibodies, visualization was performed by enhanced chemiluminescence (Amersham, Piscataway, NJ, USA). Densitometric analysis was performed using NIH Image version 1.63 software on a Macintosh computer. Densitometric analysis of actin for each sample was used to account for differences in protein loading. To reprobe the membrane, the blot was incubated for 15 min at room temperature in a sufficient volume (B20 ml) of blot stripping buffer (Pierce). The blot was then washed in buffer (0.1% Tween-20 in 1 Â PBS) for 5 min at room temperature. Before incubation with the primary antibody, the blot was blocked with either 5% milk or 3% bovine serum albumin in PBS solution containing 0.1% Tween-20.
miR isolation Fresh CD34
þ -derived miR samples from MDS patients were isolated using the mirVana miRNA isolation kit (Ambion) according to the manufacturer's instructions. Briefly, 10 5 CD34 þ cells were homogenized in 600 ml of lysis/binding buffer. A 1/10 volume of miRNA homogenate additive was added and incubated on ice for 10 min. Total RNA was extracted by adding an equal volume of acid-phenol:chloroform. Small RNA was extracted from the total RNA using a filter cartridge with 100 ml of preheated (95 1C) elution solution. The concentration of small RNA was measured using the NanoDrop, ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA).
Quantitative reverse-transcribed PCR To quantitate mRNA levels of SHIP-1 and PTEN, total RNA was harvested from normal and patient bone marrow CD34 þ cells by using Trizol (Invitrogen). Following DNase treatment, the RNA was reverse transcribed using oligo-dT primer (Invitrogen). Complementary DNA was then amplified by real-time PCR using the SYBRGreen supermix (Bio-Rad, Hercules, CA, USA) on an iCycler (Bio-Rad). Primer sets were designed to detect human SHIP-1, PTEN, Gab2 and actin. þ cells were lysed, and small RNAs (B200 nt) were extracted using mirVana miRNA isolation kit (Ambion, Austin, TX, USA). miRs were amplified and quantitated using mirVana qRT-PCR miRNA detection kit with specific reverse transcription primers and PCR primers provided by the kit (Ambion). 18S rRNA was determined to normalize the amount of small RNAs used for the PCR. Analysis was performed in triplicate, including no-template controls. Relative expression was calculated using the comparative cycle threshold method.
Immunohistochemical/immunocytochemical staining Bone marrow tissue sections (3-or 4-mm-thick) were deparaffinized in xylene and rehydrated in a graded series of ethanol. Next we performed heat-induced epitope retrieval. The antibody used was specific for pAkt (Ser473, Cell Signaling Technology, Danvers, MA, USA). The immunoreaction was detected using the LSAB þ kit (Dakocytomation, Carpinteria, CA, USA), which contains a secondary biotinylated antibody and streptavidin/horseradish peroxidase complex. We used 3,3 0 -diaminobenzidine/H 2 O 2 (Dakocytomation) as the chromogen and hematoxylin as the counterstain. Any nuclear stain with or without cytoplasmic staining of the hematopoietic cells for pAkt was considered to be a positive result, irrespective of intensity. A pAkt-positive case was defined as one having 10% or more hematopoietic cells positive for pAkt. Reactive small lymphocytes in all tissue sections served as internal positive controls for pAkt. Cytospins of CD34 þ blasts from the bone marrow of MDS patients were prepared. Next, we fixed the cells in buffered 10% formalin (Ever Scientific, Exton, PA, USA) and performed heat-induced antigen retrieval using a pressure cooker (Decloaker chamber, Biocare Medical, Concord, CA, USA). Next, the cytospin slides were placed in water to cool. The slides were then incubated in 3% hydrogen peroxide for 5 min and then rinsed with TBST (Tris-buffered saline with 0.1% Tween-20). Next, protein block was performed using the 'Background Sniper' solution (Biocare Medical) for 10 min. Further, the primary antibody was placed on the slides and incubated for 1 h. The antibody used was specific for SHIP-1 (p1c1, Santa Cruz Biotechnology). The slides were then washed three times with phosphate-buffered saline, pH 7.5 with 0.05% Tween-20 (PBST) and incubated with the secondary antibody (Mouse Envision Plus, Dako, Carpinteria, CA, USA) for 30 min. The slides were then washed with PBST and developed using diaminobenzidine (Dako). The cells were counter-stained using hematoxylin, washed with PBST and dried. The dried cytospin slides were then sealed and plated with a coverslip using Cytoseal 60 (Richard-Allan Scientific, Kalamazoo, MI, USA).
Transient transfection of SHIP-1 and pre-miR-201 in primary AML cells and myeloid cell lines Human full-length wild-type SHIP-1 cDNA with a GFP tag at the C-terminal in pEGFPC1 was a gift from Dr Gerald Krystal (The Terry Fox Laboratory, Vancouver, BC, Canada). The plasmid was cut with HindIII and BamHI, releasing the 3.7-kb SHIP-1 expression in high-risk myelodysplastic syndromes DW Lee et al fragment, which was then ligated into the HindIII and BamHI sites of pcDNA3zeo( þ ) to generate pcDNA3.1Zeo( þ )/SHIP-1. The Quick Change Site-directed Mutagenesis kit was used to mutate the two amino acids in the phosphatase region of SHIP-1 to produce phosphatase-defective SHIP-1D673G. Automated sequencing was performed to confirm the directed mutation. Cryopreserved AML samples were obtained from the Stem Cell and Xenograft Core Facility at the University of Pennsylvania School of Medicine. Samples were obtained from patients presenting with AML at the Hospital of the University of Pennsylvania. Informed consent was obtained under a protocol approved by the Institutional Review Board at the University of Pennsylvania. Transfection was carried out by nucleofection using an Amaxa Nucleofector device (Amaxa, Gaithersburg, MD, USA) under the conditions suggested by the manufacturer. 1 Â 10 6 viable primary AML cells were suspended in 100 ml of cell line Nucleofector Kit V solution with 10 mg of cDNA (SHIP or SHIPD673G) and GFP expression vector. After 24 h, GFP-positive cells were sorted, and 10 000 GFP þ cells were plated per on methylcellulose. In parallel experiments, cells were transfected with GFP-expressing vector alone. All colony counts were normalized to GFPtransfected primary cells and results displayed as percentage of GFP-transduced cells. Methylcellulose plates were cultured for 14 days in a fully humidified atmosphere at 37 1C (6.2% H 2 O, 5% CO 2 ). All samples were performed with single dilutions and triplicate plates. Following 14 days of incubation, plates were scored using an inverted microscope on the basis of cell number and colony morphology. Groups of 25 or more cells were scored as a colony. All experiments were done in triplicate and repeated three times with consistent results. Precursor miRNA (pre-miR-210) (Ambion, Grand Island, NY, USA) was transiently transfected into U937 cells with the RNAiMAX lipofectamine transfection reagent (Ambion) according to the manufacturer's recommendation. Optimal transfection efficiency was empirically determined at 3 ml RNAiMAX and 30 pM small RNA for 50 000 cells. All experiments were done in triplicate. To demonstrate direct binding of miR-210 to the 3 0 UTR of SHIP-1, we synthesized the 3 0 UTR of SHIP-1 predicted to bind to miR-210 (5 0 -TCTAGCCACCTAAAACCACGTGCCCAA-3 0 ) and a mutated version (5 0 -TCTAGCCACCTAAAACCAAACGCCCA A-3 0 ) and cloned them into pMIR-REPORT luciferase vector (Ambion) by annealing two complementary oligos and inserting it into the SpeI and HindIII sites of the vector. miR-210: 5 0 -AGUCGGCGACAGUGUGCGUGUC-3 0 , SHIP-1: 5 0 -TCTAGCCACCTAAAACCACGTGCCCAA-3 0 , mutSHIP-1: 5 0 -TCTAGCCACCTAAAACCAAACGCCCAA-3 0 . The constructs were verified by DNA sequencing. 3 Â 10 5 cells were plated in each well of a 12-well plate with Dulbecco's modified Eagle's medium and 10% fetal bovine serum. After 18 h, when cells were 50% confluent, cells were cotransfected with 180 ng pMIR-REPORTb-gal Control Plasmid (Ambion), 20 ng pMIR-REPORT-s210bs constructs or the control plasmid, and 10 pmol Pre-miR as-miR-210 miRNA precursor molecules (Ambion) or 10 pmol negative control Pre-miR molecules (Ambion) using Lipofectamine 2000 (Invitrogen). For each plasmid, six independent transfections were performed. Cells were washed twice with PBS 24 h after transfection, lysed with 200 ml Lysis buffer (Ambion), centrifuged and 10 ml supernatant was used to perform the DualLight luciferase assay following the manufacturer's manual (Dual-Light System, Ambion).
Suppression of endogenous miRNA function
We transfected commercially available anti-miR miRNA inhibitors (Ambion) directed against the mature sequences of miR-210 into two cell lines (THP1 and K562) to study the effect on SHIP-1 expression level. Up to 5 mM of anti-miR oligonucleotides (Ambion) was transfected using the Amaxa nucleofection technique into the cells. Briefly, 1 Â 10 6 cells were plated per well in a six-well plate, 24 h before transfection. Kit V of Amaxa was used for this experiment and protocol V-001 was followed. Various concentrations of miR (0, 50 pM, 2 and 5 mM) were used. Cell Nucleofector Solution V (Amaxa, Walkersville, MD, USA) was pre-warmed to room temperature and an aliquot of RPMI (10% fetal bovine serum) was warmed to 37 1C. Next, the cells were centrifuged and resuspended in 100 ml of Cell Nucleofector Solution V. In all, 100 ml of cell suspension was mixed with appropriate amount of anti-miR. Nucleofection was performed using program V-001 for high efficiency.
Statistical analysis
Statistical analysis was performed using GraphPad Prism version 4.00 for Windows (GraphPad Software, San Diego, CA, USA, http://www.graphpad.com). Normality of the distribution of the miR levels among samples was analyzed using Kolmogorov-Smirnov test. Data of samples from normal and MDS patients showed non-Gaussian distribution, and non-parametric Kruskal-Wallis one-way analysis of variance was used to compare miR levels between normal and MDS.
